38 results
6-K
EX-99.2
SPRC
SciSparc Ltd
2 May 24
Consolidated Financial Statements as for Consolidated Financial Statements as for To the shareholders of
4:02pm
Total Current Assets
Non-current assets:
Long term bank deposits
Intangible asset, net
Goodwill
4(a)
Deferred taxes
Investments in company accounted … for at equity
Long term prepaid expenses
Investments in financial assets
4(b)
Property and equipment, net
Total Non-current Assets
Total Assets
6-K
EX-99.1
SPRC
SciSparc Ltd
6 Jan 22
Report of Foreign Private Issuer
4:02pm
plan and long-term plan.
Similar to our current Compensation Policy, the equity-based compensation under the Proposed Compensation Policy for our … the alignment between the executive officers’ interests with the long term interests of the Company and its shareholders and to promote our retention efforts
6-K
EX-99.1
SPRC
SciSparc Ltd
28 Nov 23
Report of Foreign Private Issuer
4:01pm
. The adoption of the Rights Plan is intended to protect the long-term interests of SciSparc and all of our shareholders and enable them to realize … by the Rights Plan of the long-term interests of SciSparc and all of SciSparc’s shareholders and realization of the full potential value
425
olmcm1alqp35wfqkx
2 May 24
Business combination disclosure
4:46pm
6-K
EX-99.1
6yjzsf3tuftadga
11 Dec 19
Annual and Special General Meeting of Shareholders
4:38pm
6-K
EX-99.1
giquo4pb02bglr
2 May 24
Consolidated Financial Statements as for Consolidated Financial Statements as for To the shareholders of
4:02pm
6-K
EX-99.1
rbelz3zbtkx8ziv8jo
6 Dec 18
Therapix Biosciences Reports Third
6:18am
POS AM
jvugpqdrqz3kc2xncs
2 May 24
Prospectus update (post-effective amendment)
5:17pm
6-K
EX-99.1
kh595ntbep
6 Jun 18
Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update
4:55pm
6-K
8hr fcsepn2wldl33t
28 Nov 23
Report of Foreign Private Issuer
4:01pm
6-K
EX-4.1
c4skm 0msv0
25 Jan 24
SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement
9:05am
6-K
EX-1.1
rsggb9 fdue
24 Nov 20
Therapix Biosciences Announces Pricing of $4.2 Million Offering
1:13pm
F-1/A
EX-4.4
3lrlh
4 Nov 20
Registration statement (foreign) (amended)
2:14pm
6-K
EX-99.1
ri5ag
16 May 23
At-The-Market Issuance Sales Agreement
8:06pm
6-K
EX-4.1
0xl4 9u0y
24 Nov 20
Therapix Biosciences Announces Pricing of $4.2 Million Offering
1:13pm
F-1/A
EX-1.1
y7vk6j8vzcl
4 Nov 20
Registration statement (foreign) (amended)
2:14pm
20-F
x2exfd xuv3k
1 May 17
Annual report (foreign)
12:00am